🇺🇸 Paclitaxel liposome in United States

1,069 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Off Label Use — 261 reports (24.42%)
  2. Dyspnoea — 168 reports (15.72%)
  3. Neutropenia — 109 reports (10.2%)
  4. Erythema — 98 reports (9.17%)
  5. Nausea — 83 reports (7.76%)
  6. Neuropathy Peripheral — 79 reports (7.39%)
  7. Diarrhoea — 74 reports (6.92%)
  8. Asthenia — 70 reports (6.55%)
  9. Vomiting — 68 reports (6.36%)
  10. Anaemia — 59 reports (5.52%)

Source database →

Paclitaxel liposome in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Paclitaxel liposome approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Paclitaxel liposome in United States?

Sun Yat-sen University is the originator. The local marketing authorisation holder may differ — check the official source linked above.